NASDAQ:BPTH - Bio-Path Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.53 -0.03 (-1.92 %)
(As of 07/20/2018 04:00 PM ET)
Previous Close$1.53
Today's Range$1.5186 - $1.59
52-Week Range$1.25 - $5.85
Volume19,373 shs
Average Volume24,449 shs
Market Capitalization$17.69 million
P/E RatioN/A
Dividend YieldN/A
Beta2.76
Bio-Path logoBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer. The company is also developing Liposomal Bcl2 for the treatment of lymphoma; and Liposomal Stat3 that is in preclinical stage for the treatment of pancreatic cancer. It has license agreement with The University of Texas relating to the delivery technology platform for antisense nucleic acids, including two single nucleic acid drug products. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.

Receive BPTH News and Ratings via Email

Sign-up to receive the latest news and ratings for BPTH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:BPTH
CUSIPN/A
Phone832-742-1357

Debt

Debt-to-Equity RatioN/A
Current Ratio6.38
Quick Ratio6.38

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$40,000.00
Price / Sales433.76
Cash FlowN/A
Price / CashN/A
Book Value$0.71 per share
Price / Book2.15

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-7,020,000.00
Net MarginsN/A
Return on Equity-109.22%
Return on Assets-98.99%

Miscellaneous

Employees9
Outstanding Shares11,340,000
Market Cap$17.69

Bio-Path (NASDAQ:BPTH) Frequently Asked Questions

What is Bio-Path's stock symbol?

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

When did Bio-Path's stock split? How did Bio-Path's stock split work?

Bio-Path shares reverse split on the morning of Thursday, February 8th 2018. The 1-10 reverse split was announced on Friday, February 9th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, February 9th 2018. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 10 shares after the split.

How were Bio-Path's earnings last quarter?

Bio-Path Holdings Inc (NASDAQ:BPTH) announced its earnings results on Wednesday, May, 16th. The company reported ($0.17) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.20) by $0.03. View Bio-Path's Earnings History.

When is Bio-Path's next earnings date?

Bio-Path is scheduled to release their next quarterly earnings announcement on Wednesday, August, 8th 2018. View Earnings Estimates for Bio-Path.

What price target have analysts set for BPTH?

1 Wall Street analysts have issued twelve-month target prices for Bio-Path's shares. Their forecasts range from $15.00 to $15.00. On average, they expect Bio-Path's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 880.4% from the stock's current price. View Analyst Ratings for Bio-Path.

What is the consensus analysts' recommendation for Bio-Path?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."

Who are some of Bio-Path's key competitors?

Who are Bio-Path's key executives?

Bio-Path's management team includes the folowing people:
  • Mr. Peter H. Nielsen, Co-Founder, Chairman, CEO, Pres, CFO & Treasurer (Age 69)
  • Mr. Douglas P. Morris, Co-Founder, Director of Investor Relations, Sec. & Director (Age 62)
  • Mr. Anthony Price MBA, Director of Fin. and Accounting
  • Dr. Ana Tari Ashizawa, Director of Research
  • Mr. Michael Roberts, Assistant Director of Manufacturing & Supply

Has Bio-Path been receiving favorable news coverage?

Headlines about BPTH stock have been trending somewhat positive recently, according to Accern Sentiment. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Bio-Path earned a media sentiment score of 0.21 on Accern's scale. They also assigned news headlines about the company an impact score of 44.77 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Bio-Path?

Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Path's stock price today?

One share of BPTH stock can currently be purchased for approximately $1.53.

How big of a company is Bio-Path?

Bio-Path has a market capitalization of $17.69 million and generates $40,000.00 in revenue each year. Bio-Path employs 9 workers across the globe.

How can I contact Bio-Path?

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected]


MarketBeat Community Rating for Bio-Path (NASDAQ BPTH)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  174 (Vote Outperform)
Underperform Votes:  137 (Vote Underperform)
Total Votes:  311
MarketBeat's community ratings are surveys of what our community members think about Bio-Path and other stocks. Vote "Outperform" if you believe BPTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BPTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.